Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
Julien ZuberMarie FrimatSophie CaillardNassim KamarPhilippe GataultFlorent PetitprezLionel CouziNoemie Jourde-ChicheValérie ChateletRaphael GaisneDominique BertrandJamal BamoulidMagali LouisRebecca Sberro SoussanDavid NavarroPierre-Francois WesteelLuc FrimatCharlotte ColosioAntoine ThierryJoseph RivalanLaetitia AlbanoNadia ArzoukEmilie Cornec-Le GallGuillaume ClaisseMichelle EliasKhalil El KarouiSophie ChauvetJean-Philippe CoindreJean-Philippe RerolleLeila TricotJohnny SayeghCyril GarrousteChristophe CharasseYahsou DelmasZiad MassyMaryvonne HourmantAude ServaisChantal LoiratFadi FakhouriClaire Pouteil-NobleMarie-Noelle PeraldiChristophe LegendreEric RondeauMoglie Le QuintrecVéronique Frémeaux-BacchiPublished in: Journal of the American Society of Nephrology : JASN (2019)
Results from this observational study are consistent with benefit from eculizumab prophylaxis based on pretransplant risk stratification and support the need for a rigorous randomized trial.
Keyphrases